News From ADDA

ADDA Responds to Misinformation About ADD in Dr. Joyce Brothers’ Recent Column. Read more (pdf)

ADDA’s New Executive Director!
ADDA is pleased to announce the appointment of Victoria Elliott as its new Executive Director. Read More (pdf)

ADDA is Seeking AD/HD teenagers from across the US to answer our questionnaire.

The 11th Annual Conference
Plan to attend ADDA's 11th Annual ADDA Conference, New Frontiers in AD/HD, in Tucson, Arizona, May 12-15, 2005. New this year is a payment plan for ADDA members.
Read More

Lilly Announces Important Liver Safety Update to Strattera Label
Eli Lilly and Company announced that it has added a bolded warning to the product label for Strattera, an attention deficit/hyperactivity disorder (ADHD) medication. The bolded warning indicates that the medication should be discontinued in patients with jaundice (yellowing of the skin or whites of the eyes) or laboratory evidence of liver injury.
Read More

Ignore Scare Tactics About AD/HD Meds
Claims that using stimulant medication to treat Attention Deficit/Hyperactivity Disorder (AD/HD) leads to substance abuse fly in the face of scientific research, according to ADDA - the Attention Deficit Disorder Association.
Read More

Senate Resolution Declares September 7th AD/HD Awareness Day
ADDA announces success in its effort to spearhead passage of a U.S. Senate resolution designating a “National Attention Deficit Disorder Awareness Day” on September 7, 2004 – a major step toward accomplishing ADDA’s goal of spreading vital information and encouragement
Read More